Profile data is unavailable for this security.
About the company
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
- Revenue in USD (TTM)638.50m
- Net income in USD-183.17m
- Incorporated2012
- Employees925.00
- LocationAxsome Therapeutics IncOne World Trade Center, 29Th FloorNEW YORK 10007United StatesUSA
- Phone+1 (212) 332-3241
- Fax+1 (212) 320-0245
- Websitehttps://www.axsome.com/
More ▼
Mergers & acquisitions
| Acquired company | AXSM:NMQ since announced | Transaction value |
|---|---|---|
| Baergic Bio Inc | 21.58% | 83.30m |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.33bn | 8.10k | 833.54 | -- | 14.53 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.69bn | 399.00 | 10.59 | 7.05 | 10.50 | 7.62 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.44bn | 369.00 | -- | 14.86 | 6,170.46 | 10.43 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
| PTC Therapeutics, Inc. | 1.73bn | 682.64m | 5.49bn | 991.00 | 8.54 | -- | 7.61 | 3.17 | 7.77 | 7.77 | 20.73 | -2.52 | 0.7518 | 0.9143 | 10.18 | 1,746,372.00 | 29.66 | -14.19 | 44.70 | -19.65 | 97.28 | 94.76 | 39.44 | -29.50 | 2.27 | 5.24 | 1.09 | -- | 114.51 | 35.37 | 287.90 | -- | -13.07 | -- |
| Rhythm Pharmaceuticals Inc | 189.76m | -201.92m | 6.48bn | 414.00 | -- | 45.88 | -- | 34.16 | -3.11 | -3.11 | 2.92 | 4.02 | 0.435 | 0.8762 | 8.51 | 458,350.30 | -45.05 | -50.41 | -60.38 | -61.35 | 89.73 | 89.41 | -103.57 | -210.46 | 4.16 | -36.30 | 0.286 | -- | 45.83 | -- | 23.68 | -- | 34.81 | -- |
| Krystal Biotech Inc | 389.13m | 204.83m | 7.57bn | 295.00 | 37.83 | 6.20 | 35.93 | 19.44 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Halozyme Therapeutics, Inc. | 1.40bn | 316.89m | 8.24bn | 423.00 | 28.03 | 168.54 | 20.35 | 5.90 | 2.49 | 2.49 | 11.38 | 0.4144 | 0.6087 | 1.44 | 3.73 | 3,301,681.00 | 13.81 | 19.86 | 14.83 | 21.98 | 83.62 | 81.56 | 22.69 | 37.92 | 3.66 | -- | 0.9777 | 0.00 | 37.55 | 39.16 | -28.64 | 19.68 | 159.51 | -- |
| Axsome Therapeutics Inc | 638.50m | -183.17m | 8.51bn | 925.00 | -- | 95.88 | -- | 13.33 | -3.69 | -3.69 | 12.84 | 1.74 | 1.01 | 2.17 | 3.48 | 690,265.90 | -29.11 | -51.00 | -56.42 | -77.57 | 92.56 | -- | -28.69 | -76.38 | 1.48 | -25.78 | 0.6878 | -- | 65.55 | -- | 36.22 | -- | 59.92 | -- |
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.49bn | 3.22k | 33.53 | 1.89 | 26.82 | 3.57 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.72bn | 2.80k | -- | 2.92 | 36.90 | 2.82 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.70bn | 834.00 | -- | -- | -- | 25.29 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
Data as of Mar 03 2026. Currency figures normalised to Axsome Therapeutics Inc's reporting currency: US Dollar USD
31.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.82m | 7.57% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.25m | 6.44% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.47m | 2.91% |
| Invesco Advisers, Inc.as of 31 Dec 2025 | 1.15m | 2.28% |
| Deep Track Capital LPas of 31 Dec 2025 | 1.15m | 2.28% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 1.09m | 2.17% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.01m | 2.00% |
| Nomura Investment Management Business Trustas of 31 Dec 2025 | 989.45k | 1.96% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 958.15k | 1.90% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 908.48k | 1.80% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
